Romosozumab
Modify Date: 2024-09-10 18:50:48
Romosozumab structure
|
Common Name | Romosozumab | ||
|---|---|---|---|---|
| CAS Number | 909395-70-6 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of RomosozumabRomosozumab is a humanized monoclonal anti-sclerostin antibody, it promotes bone formation and inhibits bone resorption by inhibiting sclerostin. Romosozumab can be used for the research of osteoporosis[1][2]. |
| Name | Romosozumab |
|---|
| Description | Romosozumab is a humanized monoclonal anti-sclerostin antibody, it promotes bone formation and inhibits bone resorption by inhibiting sclerostin. Romosozumab can be used for the research of osteoporosis[1][2]. |
|---|---|
| Related Catalog | |
| In Vivo | Romosozumab (30 mg/kg; s.c. twice a week for 10 weeks) converts trabecular rods into trabecular plates in cynomolgus monkeys[1]. Romosozumab (3 and 30 mg/kg; s.c. once a week for 6 or 12 months) improves bone mass,architecture, and bone strength, and maintains bone quality at the same time in mature cynomolgus monkeys with 4 months post-ovariectomy[2]. Animal Model: Male cynomolgus monkeys[1] Dosage: 30 mg/kg Administration: Subcutaneous injection; 30 mg/kg twice a week for 10 weeks Result: Increased bone formation and plate-like trabecular morphology, and improved mechanical performance. |
| No Any Chemical & Physical Properties |